Celularity files Form 10-K, regains Nasdaq compliance, and refocuses strategy for growth.

Celularity Inc. has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, regaining compliance with Nasdaq's listing requirements after a delay. The company has taken strategic steps including out-licensing its biomaterials portfolio, realigning personnel, and reducing liabilities by about $13 million to strengthen its balance sheet and focus on longevity and cell therapy platforms. This marks a new chapter for Celularity as it aims to build a leaner, more resilient business targeting aging and age-related diseases through regenerative medicine. The company remains committed to operational excellence and long-term value creation for stakeholders.